Skip to main content


Pax­ton Reach­es Anoth­er Opi­oid Set­tle­ment for Texas; $225 Mil­lion Against Teva

Attorney General Paxton has reached an opioid settlement of $225 million with Teva Pharmaceutical Industries. General Paxton has fought for Texans who have been impacted by the improper marketing of opioids manufactured by the pharmaceutical companies, which have caused the tragic deaths of several thousand people every year.

February 07, 2022 | Press Release

Pax­ton Secures $63 Mil­lion Statewide Opi­oid Settlement

Texas Attorney General Ken Paxton announced a $63 million statewide opioid settlement with Endo Pharmaceuticals, Inc. The agreement will largely track the terms of the Global Prescription Opioid Litigation Settlement Agreement that was announced on July 23, 2021.

December 23, 2021 | Press Release

Pax­ton Announces Details of $290 Mil­lion Opi­oid Settlement

Texas Attorney General Ken Paxton announced a $290 million statewide opioid settlement agreement with Johnson & Johnson to resolve opioid-related claims.

October 26, 2021 | Press Release

Pax­ton Joins $21 Bil­lion Opi­oid Dis­trib­u­tor Settlement

Following on his previous announcement, Attorney General Ken Paxton announced his intention to join the $21 billion opioid distributor settlement in a press conference on Thursday.

August 05, 2021 | Press Release

Attor­ney Gen­er­al Pax­ton Announces Glob­al Opi­oid Settlement

Attorney General Ken Paxton announced a historic $26 billion agreement that will bring desperately needed relief to Texans who are struggling with opioid addiction. The agreement includes Cardinal, McKesson, and AmerisourceBergen – the nation’s three major pharmaceutical distributors – and Johnson & Johnson, which manufactured and marketed opioids.

July 23, 2021 | Press Release

Pur­due Phar­ma Files Bank­rupt­cy Plan, Estab­lish­ing Trust for Nation­wide Opi­oid Abate­ment Efforts

Texas Attorney General Ken Paxton today announced that Purdue Pharma filed its estimated $7 billion bankruptcy plan, which places the value of the company into a trust set up to allocate funds toward opioid abatement efforts across the nation.

March 17, 2021 | Press Release

AG Pax­ton: Updat­ed Set­tle­ment Reached with Opi­oid Man­u­fac­tur­er Mallinck­rodt Fol­low­ing Com­pa­ny Bankruptcy

Attorney General Ken Paxton today announced an update to a global settlement framework agreement between state attorneys general, local subdivisions, and the opioid manufacturer Mallinckrodt (MNK), its subsidiaries, and other affiliates.

October 12, 2020 | Press Release

AG Pax­ton Applauds $1.6 Bil­lion Glob­al Set­tle­ment with Opi­oid Manufacturer

Attorney General Ken Paxton today announced a global settlement framework agreement between state attorneys general, local subdivisions, and Mallinckrodt (MNK), its subsidiaries, and certain other affiliates.

February 25, 2020 | Press Release

AG Pax­ton: All U.S. Attor­neys Gen­er­al Call on Con­gress to Pass Bipar­ti­san FIGHT Fen­tanyl Act

Attorney General Ken Paxton today joined all 56 attorneys general in calling for Congress to pass the bipartisan Federal Initiative to Guarantee Health by Targeting (FIGHT) Fentanyl Act.

December 11, 2019 | Noteworthy

Attor­ney Gen­er­al Ken Pax­ton Issues State­ment on Chap­ter 11 Bank­rupt­cy Fil­ing of Pur­due Pharma

Attorney General Paxton released the following statement in response to the Chapter 11 bankruptcy filing of Purdue Pharma and all affiliated U.S. companies in the United States Bankruptcy Court for the Southern District of New York.

September 16, 2019 | Noteworthy